- Home
- REVB vs APDN Comparison
REVB vs APDN Comparison
Compare REVB & APDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- APDN
- Stock Information
- Founded
- REVB 2020
- APDN 1983
- Country
- REVB United States
- APDN United States
- Employees
- REVB N/A
- APDN N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- APDN Other Consumer Services
- Sector
- REVB Health Care
- APDN Consumer Discretionary
- Exchange
- REVB Nasdaq
- APDN Nasdaq
- Market Cap
- REVB 3.7M
- APDN 4.2M
- IPO Year
- REVB N/A
- APDN N/A
- Fundamental
- Price
- REVB $0.75
- APDN $4.98
- Analyst Decision
- REVB
- APDN
- Analyst Count
- REVB 0
- APDN 0
- Target Price
- REVB N/A
- APDN N/A
- AVG Volume (30 Days)
- REVB 2.9M
- APDN 109.6K
- Earning Date
- REVB 08-08-2025
- APDN 08-07-2025
- Dividend Yield
- REVB N/A
- APDN N/A
- EPS Growth
- REVB N/A
- APDN N/A
- EPS
- REVB N/A
- APDN N/A
- Revenue
- REVB N/A
- APDN $3,790,616.00
- Revenue This Year
- REVB N/A
- APDN $57.08
- Revenue Next Year
- REVB N/A
- APDN $40.00
- P/E Ratio
- REVB N/A
- APDN N/A
- Revenue Growth
- REVB N/A
- APDN N/A
- 52 Week Low
- REVB $0.71
- APDN $4.37
- 52 Week High
- REVB $56.00
- APDN $2,655.00
- Technical
- Relative Strength Index (RSI)
- REVB 24.83
- APDN 29.27
- Support Level
- REVB $0.74
- APDN $4.44
- Resistance Level
- REVB $0.98
- APDN $5.50
- Average True Range (ATR)
- REVB 0.06
- APDN 0.56
- MACD
- REVB 0.07
- APDN 0.46
- Stochastic Oscillator
- REVB 14.81
- APDN 7.42
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About APDN Applied DNA Sciences Inc.
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.